Company Overview - Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for kidney diseases [5] - The company's lead investigational treatment is oxylanthanum carbonate, aimed at treating hyperphosphatemia in chronic kidney disease patients on dialysis [5] - The second investigational drug, UNI-494, is intended for treating conditions related to acute kidney injury and has received orphan drug designation from the FDA for preventing Delayed Graft Function in kidney transplant patients [5] Intellectual Property - The U.S. Patent and Trademark Office has issued U.S. Patent 12,377,082 for UNI-494, ensuring intellectual property protection until 2040 [1] - This patent complements an earlier method of use patent for UNI-494 in treating Acute Kidney Injury [1] - The patent portfolio for UNI-494 supports potential partnership opportunities and future development efforts [2] Product Development - UNI-494 is a novel nicotinamide ester derivative that acts as a selective ATP-sensitive mitochondrial potassium channel activator, addressing mitochondrial dysfunction in kidney diseases [3] - The drug has completed a Phase 1 dose-ranging safety study in healthy volunteers [3] - The company is currently focused on seeking FDA approval for its lead product, oxylanthanum carbonate [2] Acute Kidney Injury Context - Acute kidney injury (AKI) is characterized by a sudden loss of kidney function, with primary causes including sepsis, ischemia, and drug-induced nephrotoxicity [4] - AKI affects 20-200 per million in the community, 7-18% of hospitalized patients, and approximately 50% of ICU patients [4] - An estimated 2 million people die from AKI globally each year, with survivors at increased risk for chronic kidney disease and end-stage renal disease [4]

Second Quarter 2025 Revenues Totaled $3.3 Million, Driven by Continued Industry Recognition of Intellectual Property Portfolio CORSICANA, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Birchtech Corp. (TSX: BCHT) (OTCQB: BCHT) ("Birchtech" or the "Company"), a leader in specialty activated carbon technologies for sustainable air and water treatment, today reported financial results for the second quarter ended June 30, 2025. Key Second Quarter 2025 & Subsequent Operational Highlights Pending final judgment follo ...

Core Insights - scPharmaceuticals Inc. has received five Notices of Allowance from the USPTO for patent applications related to its furosemide formulation, SCP-111, which is expected to have a supplemental NDA filed this quarter [1][2] - The additional patent protection is seen as a strategic achievement that enhances the company's intellectual property portfolio and supports the development of next-generation formulations [2] Company Overview - scPharmaceuticals is focused on advancing cardiorenal care through innovative treatments that address unmet patient needs [3] - The company's mission includes becoming a leading advocate for patient-centric cardiorenal care and improving global health through specialized approaches [4]

Core Viewpoint - Safe Pro Group Inc. is advancing its AI-powered computer vision technology for explosive threat detection, with recent patent applications published in Australia, Israel, and Europe, enhancing its global intellectual property protection strategy [2][4]. Group 1: Technology and Innovation - The company’s AI-powered technology has analyzed over 1.78 million drone images and identified more than 31,600 explosive threats across 7,819 hectares in Ukraine, showcasing its effectiveness in real-world applications [6]. - Safe Pro's patented Safe Pro Object Threat Detection (SPOTD) technology can detect over 150 types of small explosive threats, including landmines and unexploded ordnance, addressing a significant global challenge as nearly 60 countries are affected by landmines [5][6]. Group 2: Intellectual Property and Market Position - The publication of international patent applications under the Patent Cooperation Treaty (PCT) is a strategic move to secure exclusive rights to its technology, signaling to competitors the potential for infringement liabilities [2][4]. - The company’s existing US Patent No. 12,146,729, valid until 2043, covers autonomous detection and identification of explosives using AI, indicating the innovative nature of its technology [4]. Group 3: Industry Context and Challenges - The global landmine crisis is escalating, particularly as more European nations consider withdrawing from the Ottawa Convention, which could lead to increased threats to armed forces and allies [3]. - The company is actively pursuing global protection of its intellectual property to address the growing challenges posed by landmines and other explosive threats [3].

Extends market exclusivity for GIMOTI® to November 2038, nearly two additional years beyond original 2036 projectionSOLANA BEACH, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced the official issuance of a new U.S. patent related to its product GIMOTI®. The patent, U.S. Patent No. 12,377,064, covers the use ...

Core Insights - PALI-2108 is the first and only PDE4 inhibitor specifically designed to target the terminal ileum and colon for treating fibrostenotic Crohn's disease (FSCD) and ulcerative colitis (UC), addressing significant unmet medical needs in these conditions [1] - The inflammatory bowel disease market in China is projected to approach $1 billion in total revenues by 2030, indicating a large and growing market opportunity [1] Company Developments - The China National Intellectual Property Administration has issued a Notice of Allowance for a patent covering PALI-2108, with a base patent term extending into 2045, subject to regulatory approval extensions [2] - The CEO of Palisade Bio emphasized the importance of strengthening the global intellectual property portfolio for PALI-2108, which supports the company's clinical and strategic objectives in one of the fastest-growing pharmaceutical markets [3] - Palisade Bio is currently conducting a Phase 1b/2a clinical trial for PALI-2108 aimed at treating FSCD and UC, with multiple near-term clinical milestones expected in the next 12-18 months [3] Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, aiming to transform the treatment landscape through targeted approaches [4]

Core Viewpoint - AMTD Group Inc. and its subsidiary The Generation Essentials Group have successfully taken legal actions against Luxury Village LLC for intellectual property infringement, reinforcing their commitment to protecting their brands and trademarks [1][5]. Legal Actions and Outcomes - On July 25, 2025, AMTD secured a court order against Luxury Village LLC, mandating the cessation of prohibited operations and the relinquishment of domain names that wrongfully incorporated "lofficiel" [2]. - AMTD successfully transferred the domain names <lofficiel.au> and <lofficielfashionbook.hk> back to itself following legal proceedings [2]. - A significant victory was achieved by blocking Luxury Village LLC's bad faith application for the "L'OFFICIEL FASHION BOOK" trademark in Australia, with the Registrar of Trade Marks ruling against the application [3][4]. Intellectual Property Protection - The legal rulings emphasize AMTD's rights to intellectual property and highlight the bad faith actions of Luxury Village LLC in misleadingly suggesting an affiliation with AMTD [5]. - AMTD has taken down several infringing domain names, including <lofficiel.co>, <lofficiel.co.com>, and others, to protect its international profile and growth [6]. Caution to Partners and Public - The company warns partners and the public to avoid dealings with unauthorized entities that falsely present themselves as part of AMTD's network, such as L'Officiel Austria and others [7]. Company Overview - AMTD Group operates across various sectors, including media and entertainment, education and training, and premium assets and hospitality [8]. - AMTD IDEA Group serves as a diversified institution and digital solutions provider, connecting companies and investors with global markets [9]. - AMTD Digital Inc. offers a comprehensive digital solutions platform, focusing on digital media, content, marketing services, and hospitality [11]. - The Generation Essentials Group focuses on global strategies in multimedia, entertainment, and cultural affairs, comprising a diversified media and entertainment portfolio [12].

Core Viewpoint - GoPro, Inc. announced that an Administrative Law Judge (ALJ) of the International Trade Commission (ITC) found that Insta360 violated federal law by importing and selling products that infringe on GoPro's intellectual property related to its HERO camera design [1]. Group 1: Legal Findings - The ALJ's findings confirm that Insta360 infringed on GoPro's patent covering the HERO camera design (US Patent D789,435) and validated multiple patent claims related to GoPro's HyperSmooth video stabilization technology (US Patents 10,574,894 and 10,958,840) [2]. - GoPro plans to address other outstanding issues in its infringement case against Insta360 with the full ITC, which is expected to issue a Final Determination on all claims by November 10, 2025 [3]. Group 2: Intellectual Property and Innovation - The litigation process has enhanced GoPro's intellectual property portfolio, highlighting the company's history of innovation, which has resulted in over 1,500 US patents [3]. - GoPro's CEO, Nicholas Woodman, emphasized the company's commitment to protecting its intellectual property while welcoming fair competition that drives innovation [4].

Core Insights - Ethical Web AI has successfully onboarded its first AI Vault SaaS client via the AWS Marketplace, marking a significant milestone in its 2025 strategic roadmap [1][2] - The AI Vault product addresses key challenges in generative AI adoption, including transparency, security, and regulatory compliance, and is backed by multiple patents [2][4] - The company aims to secure five enterprise customers through AWS Marketplace by the end of the month and targets capturing 10% of the enterprise generative AI market within three years [3] Product and Innovation Strategy - Ethical Web AI's product development is driven by a strategy that emphasizes patent protection, ensuring that all software developed can be legally protected [4][5] - The company has a growing portfolio of intellectual property that underpins its product strategy, with each product linked to specific enforceable claims [5][7] - The AI Vault is specifically designed for the 27% of companies that currently prohibit generative AI due to privacy and security concerns, particularly in sectors like finance [8] Patent Portfolio - The company holds a foundational patent (US Patent 10,977,387) valued at $4.7 billion, which supports its Open-Source Platform and includes features like anonymous search [6] - Additional patent applications are in progress, enhancing capabilities such as contextual enveloping and sensitive data processing in generative AI [9] Future Outlook - Ethical Web AI aims to become cash generative within twelve months and is considering an uplist to a superior exchange like NASDAQ [11] - The company is exploring acquisition opportunities, leveraging its strong IP position and growing commercial traction [11][12] - The focus remains on scaling responsibly while delivering value to customers and shareholders [12]

Core Insights - Hoth Therapeutics has secured Japan Country Patent No. 7677628 for its HT-KIT platform, providing exclusive protection until August 27, 2039 [1][6] - The patent covers a novel method using splice-switching oligonucleotides (SSOs) to target KIT gene expression in mast cells, which are involved in various conditions including chronic hives and rare cancers [2][6] - The CEO of Hoth Therapeutics emphasized the strategic importance of this patent in the Asian pharmaceutical market and the potential for licensing opportunities [3] Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies aimed at improving patient quality of life [4] - The company is actively seeking global partners for co-development and commercialization of its therapeutic platforms, particularly in Asia [3] Patent Details - The granted patent is specifically applicable to mast cell-driven inflammatory and oncologic conditions, positioning the company for orphan indications and expedited regulatory pathways [6]